Expression of cell cycle-regulated proteins pRB2/p130, p107, E2F4, p27, and pCNA in salivary gland tumors: Prognostic and diagnostic implications

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3265-3273

  Russo, Giuseppe ^a,c   Zamparelli, Alessandra ^a   Howard, Candace M ^a   Minimo, Corrado ^b   Bellan, Cristiana ^c   Carillo, Giovanna ^d   Califano, Luigi ^d   Leoncini, Lorenzo ^c   Giordano, Antonio ^a,c   Claudio, Pier Paolo ^a  

^a Temple University   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLINE; PHOSPHOPROTEIN; PROTEIN P107; PROTEIN P130; PROTEIN P27; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F4;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SALIVARY GLAND TUMOR;

ADULT; AGED; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F4 TRANSCRIPTION FACTOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEINS; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; SALIVARY GLAND NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 20944444182     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2508     Document Type: Article

References (57)

1. Evans RW, Cruickshank AH. Epithelial tumours of the salivary glands. Major Probl Pathol 1970;1:1-299.
2. Luna MA. Pathology of tumors of the salivary glands. Philadelphia: WB Saunders Company; 1987.
3. Foote FW, Frazell EL. Tumors of major salivary glands. Cancer 1953;6:1065.
4. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177-84.
5. Kelsch RD, Bhuiya T, Fuchs A, et al. Polymorphous low-grade adenocarcinoma: flow cytometric, p53, and pCNA analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:391-9.
6. Deguchi H, Hamano H, Hayashi Y. c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignantform of the human salivary glands. Acta Pathol Jpn 1993;43:413-22.
7. Yamamoto Y, Kishimoto Y, Virmani AK, et al. Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol 1996; 27:782-6.
8. Stiegler P, Kasten M, Giordano A. The RB family of cell cycle regulatory factors. J Cell Biochem Suppl 1998;31:30-6.
9. Claudio PP, Howard CM, Baldi A, et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994;54:5556-60.
10. Zhu L, van den Heuvel S, Helin K, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993;7:1111-25.
11. Yeung RS, Bell DW, Testa JR, et al. The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene 1993;8: 3465-8.
12. Tanaka N, Sugihara K, Odajima T, et al. Oral squamous cell carcinoma: electron microscopic and immunohistochemical characteristics. Med Electron Microsc 2002;35:127-38.
13. Tanaka N, Ogi K, Odajima T, et al. pRb2/p130 protein expression is correlated with clinicopathologic findings in patients with oral squamous cell carcinoma. Cancer 2001;92:2117-25.
14. Claudio PP. Immunohistochemical investigation of new suppressor oncogene p130 in oral squamous cell carcinoma, vol. 35 (1999), 321-325. Oral Oncol 2000;36:497.
15. Tanaka N, Odajima T, Nakano T, et al. Immunohistochemical investigation of new suppressor oncogene p130 in oral squamous cell carcinoma. Oral Oncol 1999;35:321-5.
16. Helin K, Holm K, Niebuhr A, et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A 1997; 94:6933-8.
17. Claudio PP, Howard CM, Pacilio C, et al. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 2000; 60:372-82.
18. Baldi A, Esposito V, De Luca A, et al. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 1997;3:1691-7.
19. Baldi A, Esposito V, De Luca A, et al. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 1996;2:1239-45.
20. Claudio PP, Howard CM, Fu Y, et al. Mutations in the retinoblastoma- related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res 2000;60:8-12.
21. Cinti C, Claudio PP, Howard CM, et al. Genetic alterations disrupting the nuclear localization of the retinoblastoma related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 2000;60:383-9.
22. Cinti C, Leoncini L, Nyongo A, et al. Genetic alterations of the retinoblastoma related gene RB2/p130 identify different pathogenetic mechanism in and among Burkitt's lymphoma subtypes. Am J Pathol 2000;156:751-60.
23. Susini T, Baldi F, Howard CM, et al. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol 1998;16:1085-93.
24. Massaro-Giordano M, Baldi G, De Luca A, Baldi A, Giordano A. Differential expression of the retinoblastoma gene family members in choroidal melanoma: prognostic significance. Clin Cancer Res 1999;5: 1455-8.
25. Claudio PP, Russo G, Kumar CA, et al. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res 2004;10:3509-17.
26. Chittenden T, Livingston DM, DeCaprio JA. Cell cycle analysis of E2F in primary human T cells reveals novel E2F complexes and biochemically distinct forms of free E2F. Mol Cell Biol 1993;13:3975-83.
27. Ginsberg D, Vairo G, Chittenden T, et al. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 1994;8:2665-79.
28. Beijersbergen RL, Kerkhoven RM, Zhu L, et al. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 1994;8:2680-90.
29. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van't Veer LJ, Bernards R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 1995;15:3082-9.
30. Moberg K, Starz MA, Lees JA. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 1996;16:1436-49.
31. Shirodkar S, Ewen M, DeCaprio JA, et al. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992;68:157-66.
32. Cao L, Faha B, Dembski M, et al. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 1992;355:176-9.
33. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 1992;6:177-85.
34. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053-61.
35. Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev 1993;7:2392-404.
36. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 1996;10:2960-70.
37. Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D. The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci U S A 1997;94: 5095-100.
38. Puri PL, Cimino L, Fulco M, et al. Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res 1998;58:1325-31.
39. Magae J, Wu CL, Illenye S, Harlow E, Heintz NH. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J Cell Sci 1996;109:1717-26.
40. Zelterman D, Louis TA. Contingency tables in medical studies. In: Bailar MF, JC III, editors. Medical uses of statistics. Waltham (MA): NEJM Books; 1992. p. 293-310.
41. Fienberg SE. The analysis of cross-classified categorical data. Cambridge (MA): MIT Press; 1997. p. 8-23.
42. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
43. Miller RGJ. Survival analysis. New York: NY, Wiley; 1981. p. 44-102.
44. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
45. Leoncini L, Bellan C, Claudio PP, et al. Retinoblastoma related p107 and pRb2(p130) proteins in malignant lymphomas. Distinct mechanisms of cell growth control. Clin Cancer Res 1999;12:4065-72.
46. Etges A, Nunes FD, Ribeiro KC, Araujo VC. Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumuors. Oral Oncol 2004;40:326-31.
47. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/pCNA is the auxiliary protein of DNA polymerase-δ. Nature 1987;326:515-7.
48. Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987;111:841-5.
49. Frankenthaler R, Byers R, Luna M. High correlation with survival of proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of the parotid gland. Otolaryngol Head Neck Surg 1987;111:460-6.
50. Yang L, Hashimura K, Qin C, et al. Immunoreactivity of proliferating cell nuclear antigen in salivary gland tumours: an assessment of growth potential. Virchows Arch A Pathol Anat Histopathol 1993;422:481-6.
51. Ogawa I, Miyauchi M, Takata T, et al. Proliferative activity of salivary gland pleomorphic adenomas and myoepitheliomas as evaluated by the proliferating cell nuclear antigen (pCNA) labeling index (LI). J Oral Pathol Med 1993;22:447-50.
52. Corbeil HB, Branton PE. Characterization of an E2F-p130 complex formed during growth arrest. Oncogene 1997;15:657-15.
53. Smith EJ, Leone G, Nevins JR. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ 1998;9:297-303.
54. Kim YW, Otterson GA, Kratzke RA, Coxon AB, Kaye FJ. Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein. Mol Cell Biol 1994;14:7256-64.
55. Takimoto H, Tsukuda K, Ichimura K, et al. Genetic alterations in the retinoblastoma protein-related p107 gene in human hematologic malignancies. Biochem Biophys Res Commun 1998;251:264-8.
56. Claudio PR Zamparelli A, Garcia FU et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002;8:1808-15.
57. Howard CM, Claudio PP, Gallia GL, et al. Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J Natl Cancer Inst 1998;90: 1451-60.